Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that infects more than 90% of adult human population worldwide.
Chronic EBV infections are linked with malignancies of lymphoid and epithelial cell origins and with autoimmune disease such as multiple sclerosis.
HORMÆ Pharma is a privately hold biotech company that was founded in November 2020 in Lyon, France. The founders are scientists, who have a strong record in immunology, virology and medicinal chemistry as well as experience in the creation and management of biopharmaceutical companies. The company is developing small molecule therapeutics targeting the cellular receptor that control the latency/replication balance of EBV to prevent and treat EBV induced pathologies.
The company’s program results from the work initially conducted by the INSERM team of two co-founders at the International Centre for Research in Infectiology (CIRI). The library of proprietary receptors ligands was designed and synthetized by the third co-founder at Edelris.
Marlène Roy, PhD.
R&D project manager